List of all elements in the 2012 Statistical bulletin

This pages provides a listing of all elements in the 2012 Statistical bulletin. Because of its size we recommend using the interactive version to browse the data set. Statistics in the list are organised by the categories listed below and you can use the links below to jump directly to the start of a category.

General polulation surveys (GPS)

• Table GPS-0. Nationwide surveys among the general population: Bibliographic references
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (i) Survey methods.
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (ii) All adults (aged 15 - 64).
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (iii) Young adults (aged 15 - 34).
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (iv) Youth (15 - 24).
• Table GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (i) All adults (aged 15 - 64).
• Table GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (ii) Young adults (15 - 34).
• Table GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (iii) Youth (aged 15 - 24).
• Table GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (i) All adults (aged 15 - 64).
• Table GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (ii) Young adults (15 - 34).
• Table GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000.
  Part (iii) Youth (aged 15 - 24).
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (i) All adults male (aged 15 - 64).
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (ii) All adults female (aged 15 - 64).
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (iii) Young adults male (aged 15 - 34).
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (iv) Young adults female (aged 15 - 34).
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (v) Youth male (aged 15 - 24).
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (vi) Youth female (aged 15 - 24).
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (i) All adults male (aged 15 - 64).
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (ii) All adults female (aged 15 - 64).
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (iii) Young adults male (aged 15 - 34).
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (iv) Young adults female (aged 15 - 34).
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (v) Youth male (aged 15 - 24).
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (vi) Youth female (aged 15 - 24).
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (i) All adults male (aged 15 - 64).
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (ii) All adults female (aged 15 - 64).
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (iii) Young adults male (aged 15 - 34).
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (iv) Young adults female (aged 15 - 34).
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (v) Youth male (aged 15 - 24).
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
  Part (vi) Youth female (aged 15 - 24).
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys.
  Part (i) Survey methods.
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys.
  Part (ii) All adults (aged 15 -64).
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys.
  Part (iii) Young adults (aged 15 -34).
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys.
  Part (iv) Youth (aged 15 - 24).
• Table GPS-8. Last 12 months prevalence of drug use in all available national general population surveys.
  Part (i) All adults (aged 15 - 64).
• Table GPS-8. Last 12 months prevalence of drug use in all available national general population surveys.
  Part (ii) Young adults (15 - 34).
• Table GPS-8. Last 12 months prevalence of drug use in all available national general population surveys.
  Part (iii) Youth (aged 15 - 24).
• Table GPS-9. Last 30 days prevalence of drug use in all available national general population surveys.
  Part (i) All adults (aged 15 - 64).
• Table GPS-9. Last 30 days prevalence of drug use in all available national general population surveys.
  Part (ii) Young adults (15 - 34).
• Table GPS-9. Last 30 days prevalence of drug use in all available national general population surveys.
  Part (iii) Youth (aged 15 - 24).
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys.
  Part (i) All adults (aged 15 - 64) - most recent data.
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys.
  Part (ii) All adults (aged 15 - 64) - 2007 field trial.
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys.
  Part (iii) All adults (aged 15 - 64) - 2004 field trial.
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys.
  Part (iv) Young adults (aged 15 - 34) - combined sources.
• Table GPS-121. Methodological information for nation-wide surveys among the general population
• Figure GPS-1. Last 12 months prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and for youth (aged 15 - 24)
• Figure GPS-2. Continuation rates of cannabis use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-3. Last 30 days prevalence of cannabis use among youth (aged 15 - 24)
• Figure GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 - 34)
  Part (i) All countries
• Figure GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 - 34)
  Part (ii) Countries with three or more surveys
• Figure GPS-5. Last 12 months prevalence of amphetamines use among young adults (aged 15 - 34) and youth (aged 15 - 24)
• Figure GPS-6. Last 12 months prevalence of amphetamines use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
• Figure GPS-7. Last 30 days prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
• Figure GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 - 34)
  Part (i) All countries
• Figure GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 - 34)
  Part (ii) Countries with three or more surveys
• Figure GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
  Part (i) All age groups
• Figure GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
  Part (ii) Males aged 15 to 24 in countries with high prevalence rates
• Figure GPS-10. Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W)
• Figure GPS-11. Continuation rates of ecstasy use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-12. Last 12 months prevalence of cannabis use by age group
  Part (i) Selected EU-15 countries
• Figure GPS-12. Last 12 months prevalence of cannabis use by age group
  Part (ii) Selected 'new' EU countries
• Figure GPS-13. Last 12 months prevalence of cocaine use among young adults (aged 15 - 34) by gender
• Figure GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 - 34)
  Part (i) All countries
• Figure GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 - 34)
  Part (ii) Countries with three or more surveys
• Figure GPS-15. Last 12 months prevalence of cocaine use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
• Figure GPS-16. Continuation rates of cocaine use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
• Figure GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15 - 64) and young adults (aged 15 - 34)
  Part (i) Cannabis use – lifetime experience, last 12 months and last 30 days prevalence
• Figure GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15 - 64) and young adults (aged 15 - 34)
  Part (ii) Cocaine, amphetamines and ecstasy use – lifetime experience, last 12 months and last 30 days prevalence
• Figure GPS-20. Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15 - 34) in Europe, Canada, Australia and the USA
• Figure GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 - 34)
  Part (i) All countries
• Figure GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 - 34)
  Part (ii) Countries with three or more surveys
• Figure GPS-22. Continuation rates of amphetamine use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
  Part (i) United Kingdom (E&W)
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
  Part (ii) Denmark
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
  Part (iii) Germany
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
  Part (iv) Spain
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
  Part (v) France

top of page

Problem drug use (PDU)

• Table PDU-0. Estimates of prevalence of problem drug use at national and subnational level: bibliographic references
• Table PDU-1. Estimates of prevalence of problem drug use at national level: Summary Table, 2005–2010, rate per 1000 aged 15–64
  Part (i) Overall problem drug use
• Table PDU-1. Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15–64
  Part (ii) Injecting drug use
• Table PDU-1. Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15-64
  Part (iii) Problem opioid use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country
  Part (i) Estimated trends of overall problem drug use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country
  Part (ii) Estimated trends of problem opioid use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1000 population aged 15 to 64): Combined estimates per country
  Part (iii) Estimated trends of injecting drug use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1000 population aged 15 to 64): Combined estimates per country
  Part (iv) Estimated trends of problem stimulant use
• Table PDU-102. Prevalence of problem drug use at national level - full listing of studies
  Part (i) Problem drug use
• Table PDU-102. Prevalence of problem drug use at national level - full listing of studies
  Part (ii) Injecting drug use
• Table PDU-103. Prevalence of problem drug use at subnational level - full list of studies
  Part (i) Problem drug users
• Table PDU-103. Prevalence of problem drug use at subnational level - full list of studies
  Part (ii) Injecting drug users
• Table PDU-104. Trends in injecting drug use - percentage currently injecting among all clients entering treatment for primary drug heroin, 2005 to 2010
• Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2005 to 2010 - last study available
  Part (i) Estimates of overall problem drug use
• Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), 2005 to 2010 — last study available
  Part (ii) Estimates of problem opioid use
• Figure PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2005 to 2010 — last study available

top of page

Treatment demand (TDI)

• Table TDI-1. Clients entering treatment and treatment units by country, 2010 or most recent year available
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2010
  Part (i) New clients by country and year of treatment
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2010
  Part (ii) All clients by country and year of treatment
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2010
  Part (iii) Reporting treatment units by country and year of treatment
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2010
  Part (iv) Types of reporting treatment unit by country
• Table TDI-3. New clients entering treatment by primary drug, 1998 to 2010
  Part (i) New heroin clients by country and year of treatment (%)
• Table TDI-3. New clients entering treatment by primary drug, 1998 to 2010
  Part (ii) New cocaine clients by country and year of treatment (%)
• Table TDI-3. New clients entering treatment by primary drug, 1998 to 2010
  Part (iii) New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)
• Table TDI-3. New clients entering treatment by primary drug, 1998 to 2010
  Part (iv) New cannabis clients by country and year of treatment (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2010 or most recent year available
  Part (i) New clients by country and gender (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2010 or most recent year available
  Part (ii) All clients by country and gender (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2010 or most recent year available
  Part (iii) New clients by country and age (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2010 or most recent year available
  Part (iv) All clients by country and age (%)
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available
  Part (i) New clients by country and primary drug (%), regardless whether they inject the drug
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available
  Part (ii) All clients by country and primary drug (%), regardless whether they inject the drug
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available
  Part (iii) New clients by country and rates of injection of primary drug (%)
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available
  Part (iv) All clients by country and rates of injection of primary drug (%)
• Table TDI-6. Incidence of treatment demand for drug use, 2010 or most recent year available.
  Part (0) New clients by country (rate per 100 000 population aged 15 to 64 years old)
• Table TDI-7. Data coverage, 2010 or most recent year available
  Part (i) Clients entering treatment by country and type of treatment centre and type of client
• Table TDI-7. Data coverage, 2010 or most recent year available
  Part (ii) Units by country and type of treatment centre and reporting status
• Table TDI-8. Primary use of stimulants of clients entering treatment, 2010 or most recent year available
  Part (i) New clients by country and type of stimulant (%)
• Table TDI-8. Primary use of stimulants of clients entering treatment, 2010 or most recent year available
  Part (ii) All clients by country and type of stimulant (%)
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available
  Part (i) New outpatient clients by country and gender
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available
  Part (ii) All outpatient clients by country and gender
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available
  Part (iii) New outpatient clients by country and age
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available
  Part (iv) All outpatient clients by country and age
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients, age distribution by primary drug (%)
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (ii) New outpatient clients, primary drug distribution by age (%)
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (iii) All outpatient clients, age distribution by primary drug (%)
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (iv) All outpatient clients, primary drug distribution by age (%)
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (v) New inpatient clients, age distribution by primary drug (%)
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (vi) New inpatient clients, primary drug distribution by age (%)
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (vii) All inpatient clients, age distribution by primary drug (%)
• Table TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (viii) All inpatient clients, primary drug distribution by age (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients, age at first use distribution by primary drug (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (ii) New outpatient clients, primary drug distribution by age at first use (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (iii) All outpatient clients, age at first use distribution by primary drug (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (iv) All outpatient clients, primary drug distribution by age at first use (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (v) New inpatient clients, age at first use distribution by primary drug (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (vi) New inpatient clients, primary drug distribution by age at first use (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (vii) All inpatient clients, age at first use distribution by primary drug (%)
• Table TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
  Part (viii) All inpatient clients, primary drug distribution by age at first use (%)
• Table TDI-12. Education status of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients by country and education status (%)
• Table TDI-12. Education status of clients entering treatment, 2010 or most recent year available
  Part (ii) All outpatient clients by country and education status (%)
• Table TDI-12. Education status of clients entering treatment, 2010 or most recent year available
  Part (iii) New inpatient clients by country and education status (%)
• Table TDI-12. Education status of clients entering treatment, 2010 or most recent year available
  Part (iv) All inpatient clients by country and education status (%)
• Table TDI-13. Labour status of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients by country and labour status (%)
• Table TDI-13. Labour status of clients entering treatment, 2010 or most recent year available
  Part (ii) All outpatient clients by country and labour status (%)
• Table TDI-13. Labour status of clients entering treatment, 2010 or most recent year available
  Part (iii) New inpatient clients by country and labour status (%)
• Table TDI-13. Labour status of clients entering treatment, 2010 or most recent year available
  Part (iv) All inpatient clients by country and labour status (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients by country and with whom living (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2010 or most recent year available
  Part (ii) All outpatient clients by country and with whom living (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2010 or most recent year available
  Part (iii) New inpatient clients by country and with whom living (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2010 or most recent year available
  Part (iv) All inpatient clients by country and with whom living (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2010 or most recent year available
  Part (i) New clients entering outpatient treatment by country and type of accommodation (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2010 or most recent year available
  Part (ii) All clients entering outpatient treatment by country and type of accommodation (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2010 or most recent year available
  Part (iii) New clients entering inpatient treatment by country and type of accommodation (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2010 or most recent year available
  Part (iv) All clients entering inpatient treatment by country and type of accommodation (%)
• Table TDI-16. Source of referral of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients by country and source of referral (%)
• Table TDI-16. Source of referral of clients entering treatment, 2010 or most recent year available
  Part (ii) All outpatient clients by country and source of referral (%)
• Table TDI-16. Source of referral of clients entering treatment, 2010 or most recent year available
  Part (iii) New inpatient clients by country and source of referral (%)
• Table TDI-16. Source of referral of clients entering treatment, 2010 or most recent year available
  Part (iv) All inpatient clients by country and source of referral (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (i) New opioid outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (ii) All opioid outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (iii) New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (iv) All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (ix) New cannabis outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (v) New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (vi) All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (vii) New hypnotics and sedatives outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (viii) All hypnotics and sedatives outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
  Part (x) All cannabis outpatient clients by country and usual route of administration (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients by primary drug and frequency of use (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available
  Part (ii) All outpatient clients by primary drug and frequency of use (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available
  Part (iii) New inpatient clients by primary drug and frequency of use (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available
  Part (iv) All inpatient clients by primary drug and frequency of use (%)
• Table TDI-19. Primary drug of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients by country and primary drug (%)
• Table TDI-19. Primary drug of clients entering treatment, 2010 or most recent year available
  Part (ii) All outpatient clients by country and primary drug (%)
• Table TDI-19. Primary drug of clients entering treatment, 2010 or most recent year available
  Part (iii) New inpatient clients by country and primary drug (%)
• Table TDI-19. Primary drug of clients entering treatment, 2010 or most recent year available
  Part (iv) All inpatient clients by country and primary drug (%)
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available
  Part (i) New outpatient clients, ratio of males to females by country and primary drug
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available
  Part (ii) All outpatient clients, ratio of males to females by country and primary drug
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available
  Part (iii) New inpatient clients, ratio of males to females by country and primary drug
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available
  Part (iv) All inpatient clients, ratio of males to females by country and primary drug
• Table TDI-22. Secondary drugs cited by clients entering treatment, 2010 or most recent year available
  Part (i) Outpatient units
• Table TDI-22. Secondary drugs cited by clients entering treatment, 2010 or most recent year available
  Part (ii) Inpatient units
• Table TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2010 or most recent year available
  Part (i) New clients by country and primary drug and type of treatment centre (%)
• Table TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2010 or most recent year available
  Part (ii) All clients by country and primary drug and type of treatment centre (%)
• Table TDI-25. Age distribution of all clients entering outpatient treatment by primary drug and gender, 2010 or most recent year available
• Table TDI-32. Mean age of clients entering treatment by primary drug and gender, 2010 or most recent year available
  Part (i) Outpatient clients
• Table TDI-32. Mean age of clients entering treatment by primary drug and gender, 2010 or most recent year available
  Part (ii) Inpatient clients
• Table TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2010 or most recent year available
  Part (i) Outpatient units
• Table TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2010 or most recent year available
  Part (ii) Inpatient units
• Table TDI-36. Primary amphetamine use among new clients entering treatment (%), 2005 to 2010
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available
  Part (i) All clients by country and primary drug and type of treatment unit
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available
  Part (ii) Outpatient clients by primary drug and mean age, gender ratio
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available
  Part (iii) Inpatient clients by primary drug and mean age, gender ratio
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available
  Part (iv) Outpatient clients by secondary drug and primary drug
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available
  Part (v) Inpatient clients by secondary drug and primary drug
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (i) New opioid outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iii) New stimulants (other than cocaine) outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iv) New hallucinogen outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (v) New hypnotics and sedatives outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (vi) New volatile inhalant outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (vii) New cannabis outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (viii) New 'other drugs' outpatient clients by country and by age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (i) All opioid outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iii) All stimulants (other than cocaine) outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iv) All hallucinogen outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (v) All hypnotics and sedatives outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (vi) All volatile inhalant outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (vii) All cannabis outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
  Part (viii) All 'other drugs' outpatient clients by country and by age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (i) New opioid inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iii) New stimulants (other than cocaine) inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iv) New hallucinogen inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (v) New hypnotics and sedatives inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (vii) New cannabis inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (viii) New 'other drugs' inpatient clients by country and by age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (i) All opioid inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iii) All stimulants (other than cocaine) inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (iv) All hallucinogen inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (v) All hypnotics and sedatives inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (vi) All volatile inhalant inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (vii) All cannabis inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
  Part (viii) All 'other drugs' inpatient clients by country and by age
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (i) New opioid outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iii) New stimulants (other than cocaine) outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iv) New hallucinogen outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (v) New hypnotics and sedatives outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vi) New volatile inhalant outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vii) New cannabis outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (viii) New 'other drugs' outpatient clients by country and by age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (i) All opioid outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iii) All stimulants (other than cocaine) outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iv) All hallucinogen outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (v) All hypnotics and sedatives outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vi) All volatile inhalant outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vii) All cannabis outpatient clients by country and by age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (viii) All 'other drugs' outpatient clients by country and by age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (i) New opioid inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iii) New stimulants (other than cocaine) inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iv) New hallucinogen inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (v) New hypnotics and sedatives inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vi) New volatile inhalant inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vii) New cannabis inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (viii) New 'other drugs' inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (i) All opioid inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iii) All stimulants (other than cocaine) inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (iv) All hallucinogen inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (v) All hypnotics and sedatives inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vi) All volatile inhalant inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (vii) All cannabis inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (viii) All 'other drugs' inpatient clients by country and by age at first use
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (i) New opioid outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (ii) All opioid outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (iii) New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (iv) All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (v) New stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (vi) All stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (vii) New cannabis outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
  Part (viii) All cannabis outpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (i) New opioid inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (ii) All opioid inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (iii) New cannabis inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (iv) All cannabis inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (v) New stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (vi) All stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (vii) New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
  Part (viii) All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
• Table TDI-113. All clients entering treatment for opioids by country and type of opioid misused (%), 2010 or most recent year available
• Table TDI-114. Primary opioids distribution among all clients entering treatment by country and type of treatment centre (%), 2010
• Table TDI-115. HCL and Crack use of clients entering outpatient treatment , 2010 or most recent year available
  Part (i) New outpatient clients by country and type of cocaine product
• Table TDI-115. HCL and Crack use of clients entering outpatient treatment , 2010 or most recent year available
  Part (ii) All outpatient clients by country and type of cocaine product
• Figure TDI-1. Trend in estimated number of new clients entering treatment by selected primary drugs, 2005 to 2010
  Part (i) Percentage by primary drug
• Figure TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2005 to 2010
  Part (ii) Numbers of clients by primary drug
• Figure TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2010.
  Part (i) New clients
• Figure TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2010.
  Part (ii) All clients
• Figure TDI-3. Trend in estimated number of all clients entering treatment by selected primary drug used, 2005 to 2010
  Part (i) Percentage by primary drug
• Figure TDI-3. Trend in estimated number of all clients entering treatment by selected primary drugs, 2005 to 2010
  Part (ii) Numbers of clients by primary drug
• Figure TDI-7. New outpatient clients injecting opioid as primary drug from 2005 to 2010 in 18 countries supplying data

top of page

Drug-related deaths (DRD)

• Table DRD-0. Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references
• Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
  Part (i) Demographic characteristics, 2010 or last year with available information
• Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
  Part (ii) Numbers of drug-induced deaths and toxicology, 2010 or last year with available information
• Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
  Part (iii) Demographic characteristics and toxicology, 1990 or earliest year with available information
• Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
  Part (i) Total drug-induced deaths, 1995 to 2010
• Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
  Part (ii) Male drug-induced deaths, 1995 to 2010
• Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
  Part (iii) Female drug-induced deaths, 1995 to 2010
• Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
  Part (iv) Total drug-induced deaths under the age of 25 years, 1995 to 2010
• Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
  Part (v) Totals and indexes, 1995 to 2010
• Table DRD-3. Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2010
• Table DRD-4. Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2010
• Table DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
  Part (i) Population mortality rates, 2010 or last year with available information
• Table DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
  Part (ii) Proportional mortality due to drug-induced deaths, 2009 or last year with available information.
• Table DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
  Part (iii) Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use
• Table DRD-106. Methodological features of drug-induced deaths reported by National Reitox Focal Points (Based on national definitions - Reitox Standard Table 5)
• Table DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions
  Part (i) Total drug-induced deaths, 1985 to 2010
• Table DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions
  Part (ii) Totals and indexes, 1985 to 2010
• Table DRD-108. Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2011 National Reports)
• Figure DRD-1. Proportion of drug-induced deaths that show presence of opioids for the most recent year reported
• Figure DRD-2. Proportion of drug-induced deaths occurring under the age of 25 years for the most recent year reported
• Figure DRD-3. Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2010
• Figure DRD-4. Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2010
• Figure DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25
  Part (i) Indexed trend in the EU-15 Member States and Norway 1990–2009
• Figure DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25
  Part (ii) Indexed trend in the new Member States, 1990–2009
• Figure DRD-6. Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2009
• Figure DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported
  Part (i) Mortality rates per million among all adults (15 to 64 years) due to drug-related deaths
• Figure DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported
  Part (ii) Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to HIV/AIDS attributable to injection drug use
• Figure DRD-8. Indexed long term trend in drug-induced deaths in the EU-15 Member States and Norway, 1985 to 2009
• Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average)
  Part (i) Some EU Member States and Norway, 1990 to 2010
• Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average)
  Part (ii) Some EU Member States, 1990 to 2010
• Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average)
  Part (iii) Some EU countries, 1990 to 2010
• Figure DRD-10. Mean age of drug-induced deaths in EU Member States, last year with available data
• Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole
  Part (i) Index in some Member States, 1985 to 2010
• Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole
  Part (ii) Index in some Member States, 1985 to 2010
• Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole
  Part (iii) Index in some Member States, 1985 to 2010
• Figure DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway
  Part (i) Changes between 2000 and 2003
• Figure DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway
  Part (ii) Changes between 2003 and 2009/10
• Figure DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions.
  Part (i) EU-15 Member States and Norway 1990–2009
• Figure DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions.
  Part (ii) New Member States, 1990–2009

top of page

Drug-related infectious diseases (INF)

• Table INF-0. Bibliographic references
• Table INF-1. Prevalence of HIV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country
• Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country
• Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (i) HIV infection in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (ii) HIV infection in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (iii) AIDS incidence in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (iv) AIDS incidence in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway
  Part (i) Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor
• Table INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway
  Part (ii) Case definitions
• Table INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway
  Part (i) Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor
• Table INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway
  Part (ii) Case definitions
• Table INF-108. Prevalence of HIV infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
• Table INF-109. Prevalence of HIV infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
• Table INF-110. Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
• Table INF-111. Prevalence of hepatitis C infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
• Table INF-112. Prevalence of hepatitis C infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
• Table INF-113. Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
• Table INF-114. Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg), 1991 to 2010. EU countries, Croatia, Turkey and Norway
• Table INF-115. Prevalence of antibodies against hepatitis B virus among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
• Figure INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2010
  Part (i) EU countries, Croatia, Turkey and Norway
• Figure INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2010
  Part (ii) Non-EU countries of the WHO European region
• Figure INF-02. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010.
  Part (i) EU countries, Croatia, Turkey and Norway: five highest countries in peak value 2005-2010
• Figure INF-02. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010.
  Part (ii) EU countries, Croatia, Turkey and Norway: countries with 5 to 10 cases per million population in peak value 2005-2010
• Figure INF-02. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010.
  Part (iii) Non-EU countries of WHO European region with over 50 cases per million population in peak value 2005-2010
• Figure INF-02. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010.
  Part (iv) Non-EU countries of WHO European region with 10 to 50 cases per million population in peak value 2005-2010
• Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage
  Part (i) All injecting drug users, 2009 to 2010
• Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage
  Part (ii) Young injecting drug users (under age 25), 2009 to 2010
• Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage
  Part (iii) New injecting drug users (injecting less than 2 years), 2009 to 2010
• Figure INF-6. HCV antibody prevalence among injecting drug users - studies with national and subnational coverage
  Part (i) All injecting drug users, 2009 to 2010
• Figure INF-6. HCV antibody prevalence among injecting drug users - studies with national and subnational coverage
  Part (ii) Young injecting drug users (under age 25), 2009 to 2010
• Figure INF-6. HCV antibody prevalence among injecting drug users - studies with national and subnational coverage
  Part (iii) New injecting drug users (injecting less than 2 years), 2009 to 2010
• Figure INF-9. Prevalence of markers of HBV infection among injecting drug users — studies with national and subnational coverage
  Part (i) Percentage ever infected (positive for aHBc), 2009 to 2010
• Figure INF-9. Prevalence of markers of HBV infection among injecting drug users - studies with national and subnational coverage
  Part (ii) Percentage with current infection (positive for HBsAg), 2009 to 2010

top of page

Youth and the schools population (EYE)

• Table EYE-0. School surveys: Sources
• Table EYE-08. HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old
• Table EYE-9. HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
  Part (i) All students
• Table EYE-9. HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
  Part (ii) Males
• Table EYE-9. HBSC school surveys (2009/10) percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
  Part (iii) Females
• Table EYE-10. Recent school surveys (2005-2011): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old
• Table EYE-11. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years
• Table EYE-20. ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (i) All students
• Table EYE-20. ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (ii) Males
• Table EYE-20. ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (iii) Females
• Table EYE-21. ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
  Part (i) All students
• Table EYE-21. ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
  Part (ii) Males
• Table EYE-21. ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
  Part (iii) Females
• Table EYE-22. All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (i) All students
• Table EYE-22. All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (ii) Males
• Table EYE-22. All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (iii) Females
• Table EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
  Part (i) All students
• Table EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
  Part (ii) Males
• Table EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
  Part (iii) Females
• Table EYE-30. Recent School Surveys (2003-2011): percentage lifetime prevalence of psychoactive substance use and last month prevalence of cannabis among students aged 17-18 years old
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (i) Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (ii) Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (iii) Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (iv) Comparison of lifetime prevalence of cannabis use with perceived great risk (percentages), among 15/16 year olds school students in 2007/2011

top of page

Drug law offences (DLO)

• Table DLO-1. Drug law offences, 1995 to 2010
  Part (i) Number of reports of offences
• Table DLO-1. Drug law offences, 1995 to 2010
  Part (ii) Number of reports of persons
• Table DLO-1. Drug law offences, 1995 to 2010
  Part (iii) Methodological notes
• Table DLO-2. Offence types in reports for drug law offences, 2009 or 2010
  Part (i) Number and percentage of all reports for drug law offences
• Table DLO-2. Offence types involved in reports for drug law offences: methods of percentages calculation for drug law offences
  Part (ii) Methodological notes
• Table DLO-3. Drug types in reports for drug law offences, 2009 or 2010
  Part (i) Number and percentage of all reports for drug law offences
• Table DLO-3. Drug types in reports for drug law offences
  Part (ii) Methodological notes
• Table DLO-4. Drug law offences related to drug use or possession for use, 2003 to 2010
  Part (i) Number and percentage
• Table DLO-4. Drug law offences related to drug use or possession for use, 2003 to 2010
  Part (ii) Methodological notes
• Table DLO-5. Drug law offences related to drug supply, 2003 to 2010
  Part (i) Number and percentage
• Table DLO-5. Drug law offences related to drug supply, 2003 to 2010
  Part (ii) Methodological notes
• Table DLO-6. Cannabis-related offences, 2003 to 2010
  Part (i) Number and percentage of all drug law offences
• Table DLO-6. Cannabis-related offences, 2003 to 2010
  Part (ii) Methodological notes
• Table DLO-7. Heroin-related offences, 2003 to 2010
  Part (i) Number and percentage of all drug law offences
• Table DLO-7. Heroin-related offences, 2003 to 2010
  Part (ii) Methodological notes
• Table DLO-8. Cocaine-related offences, 2003 to 2010
  Part (i) Number and percentage of all drug law offences
• Table DLO-8. Cocaine-related offences, 2003 to 2010
  Part (ii) Methodological notes
• Table DLO-109. Number of reports for drug law offences, 1985 to 2010
  Part (i) Number of reports of offences
• Table DLO-109. Number of reports for drug law offences, 1985 to 2010
  Part (ii) Number of reports of persons
• Table DLO-109. Number of reports for drug law offences, 1985 to 2010
  Part (iii) Methodological notes
• Figure DLO-1. Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States, 2005–10
• Figure DLO-2. Offence types in reports for drug law offences in the EU Member States, Croatia and Norway, 2009 or 2010
• Figure DLO-3. Indexed trends in reports for drug law offences by type of drug in the EU Member States, 2005–10
• Figure DLO-4. Indexed trends in reports for offences related to drug use or possession for use in the EU Member States, 2005–10
• Figure DLO-5. Indexed trends in reports for offences related to drug supply in the EU Member States, 2005–10

top of page

Drug use in prison (DUP)

• Table DUP-0. Prevalence of drug use among prisoners — Sources and bibliographic references
• Table DUP-1. Prevalence of lifetime drug use among prisoners, 2000–2010
• Table DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2000–2010
• Table DUP-3. Prevalence of drug use within prison among prisoners, 2000–2010
• Table DUP-4. Prevalence of injecting drug use within prison among prisoners, 2000–2010
• Table DUP-105. Prevalence (percentage) of drug use among prisoners in EU member states and Norway - full listing of studies

top of page

Health and social responses (HSR)

• Table HSR-1. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine
• Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway
  Part (i) Legal framework regarding the initiation of OST by substitution medication
• Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway
  Part (ii) Legal framework regarding the continuation of OST by substitution medication
• Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway
  Part (iii) Legal framework regarding the dispensing of substitution medications
• Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST)
  Part (i) Estimates of clients in methadone treatment or any opioid substitution in EU-27, Croatia, Turkey and Norway, 1993 - 2010
• Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST)
  Part (ii) Estimates and share of clients in methadone (MMT) and buprenorphine-based opioid substitution treatment in EU-27, Croatia, Turkey and Norway in 2010 or latest available year
• Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST)
  Part (iii) Methodological notes EU-27, Croatia, Turkey and Norway, 2003 - 2010
• Table HSR-4. Needle and syringe programmes (NSPs)
  Part (i) Year of introduction of needle and syringe programmes (NSPs), types of programmes available in 2010 and number of sites
• Table HSR-4. Needle and syringe programmes (NSPs)
  Part (ii) NSP geographical coverage, 2010 or latest available year
• Table HSR-5. Provision of needle and syringe programmes (NSPs)
  Part (i) Syringes provided through needle and syringe programmes (NSPs), 2003-2010
• Table HSR-5. Provision of needle and syringe programmes (NSPs)
  Part (ii) Clients and contacts at specialist NSP agencies, 2009-2010
• Table HSR-6. Hepatitis responses in Europe
  Part (i) Hepatitis B immunization in EU27, Croatia, Turkey and Norway
• Table HSR-6. Hepatitis responses
  Part (ii) Availability of Hepatitis C testing in EU27, Croatia, Turkey and Norway
• Table HSR-7. Availability of selected health responses in prison in EU-27, Croatia, Turkey and Norway
• Table HSR-8. Responses to drug related deaths in Europe
  Part (i) Availability of selected responses to reduce drug related deaths in 27 EU countries, Norway and Turkey (expert ratings)
• Table HSR-8. Responses to drug related deaths in Europe
  Part (ii) Availability of information material on drug-related deaths and emergencies for specific target groups in 27 EU countries, Norway and Turkey
• Table HSR-9. Opioid substitution treatment in prison in EU 27, Croatia, Turkey and Norway
• Table HSR-10. Estimation of the total number of clients in treatment in 2010 or latest available year
• Figure HSR-1. Opioid substitution treatment coverage
  Part (i) Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users, 2010 or most recent year available
• Figure HSR-1. Opioid substitution treatment coverage
  Part (ii) Overall estimated number of problem opioid users in treatment (in opioid substitution treatment and other treatments) as a percentage of the estimated number of problem opioid users, 2010 or most recent year available
• Figure HSR-2. Estimated number of clients in opioid substitution treatment (OST) in EU15-12, 1993 - 2010.
• Figure HSR-3. Syringes distributed through specialised programmes in 2010 per estimated IDU
• Figure HSR-4. Proportion of prison population receiving opioid substitution treatment (OST) on a given day in 2010 or latest available year

top of page

Seizures data (SZR)

• Table SZR-0. Seizures of illicit drugs
  Part (i) Data source: name of institution and name of monitoring system/study
• Table SZR-0. Seizures of illicit drugs
  Part (ii) Methodological comments
• Table SZR-1. Number of cannabis resin seizures, 1995 to 2010
• Table SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2010
• Table SZR-3. Number of herbal cannabis seizures, 1995 to 2010
• Table SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2010
• Table SZR-5. Number of seizures of cannabis plants, 1995 to 2010
• Table SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2010
  Part (i) Number of plants, 1995 to 2010
• Table SZR-6. Quantities (Kg) of cannabis plants seized, 1995 to 2010
  Part (ii) Quantity (Kg) of plants, 1995 to 2010
• Table SZR-7. Number of heroin seizures 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-8. Quantities (kg) of heroin seized 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-9. Number of cocaine seizures 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-10. Quantities (kg) of cocaine seized 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-11. Number of amphetamine seizures 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-12. Quantities (kg) of amphetamine seized 1995 to 2010
  Part (i) Quantities (kg) of amphetamine, 1995 to 2010
• Table SZR-12. Quantities (tablets) of amphetamine seized 1995 to 2010
  Part (iii) Quantity (tablets) of amphetamine, 1995 to 2010
• Table SZR-13. Number of ecstasy seizures 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-14. Quantities (tablets) of ecstasy seized 1995 to 2010
  Part (i) Quantity (tablets) of ecstasy, 1995 to 2010
• Table SZR-14. Quantities (Kg) of ecstasy seized 1995 to 2010
  Part (iii) Quantity (Kg) of ecstasy, 1995 to 2010
• Table SZR-15. Number of LSD seizures 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-16. Quantities (units) of LSD seized 1995 to 2010
  Part (i) 1995 to 2010
• Table SZR-17. Number of methamphetamine seizures, 2001 to 2010
• Table SZR-18. Quantities (kg) of Methamphetamine seized 2001 to 2010
• Table SZR-19. Number of crack cocaine seizures, 1995-2010
• Table SZR-20. Quantities (kg) of crack cocaine seized 1995 to 2010
• Table SZR-21. Other substances seized, 2004 to 2010
  Part (i) Other substances siezed not included in other SZR tables, 2004 to 2010
• Figure SZR-1. Estimated number of heroin seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010.
• Figure SZR-2. Estimated number of cocaine seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010.

top of page

Price and purity information (PPP)

• Table PPP-1. Price of cannabis products at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal price in euros
• Table PPP-1. Price of cannabis products at retail level, 2010
  Part (ii) Sources of information
• Table PPP-1. Price of cannabis products at retail level, 2010
  Part (iii) Geographical coverage / Methodology
• Table PPP-2. Price of heroin at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal price in euros
• Table PPP-2. Price of heroin at retail level, 2010
  Part (ii) Sources of information
• Table PPP-2. Price of heroin at retail level, 2010
  Part (iii) Geographical coverage / Methodology
• Table PPP-3. Price of cocaine products at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal price in euros
• Table PPP-3. Price of cocaine products at retail level, 2010
  Part (ii) Sources of information
• Table PPP-3. Price of cocaine products at retail level, 2010
  Part (iii) Geographical coverage / Methodology
• Table PPP-4. Price of synthetic drugs at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal price in euros
• Table PPP-4. Price of synthetic drugs at retail level, 2010
  Part (ii) Sources of information
• Table PPP-4. Price of synthetic drugs at retail level, 2010
  Part (iii) Geographical coverage / Methodology
• Table PPP-5. Potency of cannabis products at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal potency recorded, measured as percentage of THC content
• Table PPP-5. Potency of cannabis products at retail level, 2010
  Part (ii) Sources of information
• Table PPP-5. Potency of cannabis products at retail level, 2010
  Part (iii) Geographical coverage / Sampling frame / Type of study
• Table PPP-6. Purity of heroin at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
• Table PPP-6. Purity of heroin at retail level, 2010
  Part (ii) Sources of information
• Table PPP-6. Purity of heroin at retail level, 2010
  Part (iii) Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt
• Table PPP-7. Purity of cocaine products at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
• Table PPP-7. Purity of cocaine products at retail level, 2010
  Part (ii) Sources of information
• Table PPP-7. Purity of cocaine products at retail level, 2010
  Part (iii) Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt
• Table PPP-8. Purity of synthetic drugs at retail level, 2010
  Part (i) Minimum, maximum, mean, median and modal purity recorded
• Table PPP-8. Purity of synthetic drugs at retail level, 2010
  Part (ii) Sources of information
• Table PPP-8. Purity of synthetic drugs at retail level, 2010
  Part (iii) Geographical coverage / Sampling frame / Type of study
• Table PPP-9. Composition of illicit drug tablets, 2010
  Part (i) Content of synthetic scheduled illicit drugs
• Table PPP-9. Composition of illicit drug tablets, 2010
  Part (ii) Sources of information
• Table PPP-9. Composition of illicit drug tablets, 2010
  Part (iii) Sampling frame / Type of monitoring system
• Table PPP-9. Composition of illicit drug tablets, 2010
  Part (iv) Information available on substances listed in categories 'Miscellaneous' and 'Other'
• Table PPP-9. Composition of illicit drug tablets, 2010
  Part (v) Information available on adulterants, cutting agents and/or impurities.
• Figure PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2005–10
• Figure PPP-2. : Indexed trends in EU potency/purity for major drug types, adjusting for population size, 2005-2010